an financial I'll before And I'll Laurie, for call, an Thank on everyone. update including will you, then call, share prepare provide launch taking the our this developments, our provide summarize we’re for to we Chuck commercial line open programs. CFO, remarks, year. questions. a of R&D update this will aggressive Ryan, since closing recently and appointed afternoon, results. last steps our good on key attorney's potential our out earnings On
started. let's So get
the out including of the on update capabilities about few are released. believe we important our and towards The worth advance about. milestones that its takeaways specifics. excited we on building data number I'd be of and for high out in point long-term priorities touch significant our for achieving with and level, commercial with We lot to there of latest highlight key including commercial adagrasib CNS these progress and ASCO, the made second strategic very ability and was significant Mirati, potential excited pembrolizumab a as one results like ASCO, points the both and will concurrent a near Chuck quarter, to success. important well second very a to noting in a lot quarter and important At us At productive presenting data adagrasib of shared combine that several a differentiation, was aggressive penetration, at position be and a launch. we
ability in is results company. adagrasib Our of and a secure launch which to key commercial the execute cancer, US beyond us confidence and line cell give lung approval strong non-small for and our priority a a second
We GXXC the formulation. in especially tablet KRAS very market, are the in competing inhibitor comfortable
and adagrasib and productive, date no that, clarity have voiced closely through of will to application. approval. The studies for review are the major new to no there we and expectations with Our new to advisory be the and has REMS added safety ongoing had continue recently FDA interactions prior review mid-cycle We committee or FDA program. collaborate our drug effectively no issues
readiness approval plans. a the finalizing for As such, our commercial formulation with we tablet are and preparing are of the NDA
customer-facing commercial greater hired talent have force, XXX drive to the the PDUFA successful remainder than date XX, reminder, we but We person a US to ready be we our comes is before then. a December will go and approval needed of field As if believe launch. recently
patient access, to support In have addition, market our successful execute we've organization place affairs a the commercial and our capabilities, of commercial and in necessary components now medical built strategies. all out marketing,
will team commercial be third ready the launch the and trained Our the in quarter. fully end US of by
have and I'm commercial very you I the assemble experience pharma considerable without know the caliber and hesitation, team have say biotech, been in can Some impressed and Mirati. quality I at able we to of of with
commercial us is on successful. built Our that enable be we will strategy several believe pillars to
in date XX-hour pooled First, us adagrasib data, enabled of meaningful presented longest overall differentiating molecular the the response have lung half-life months analysis. than patients including than XX metastases, recently and with cancer greater median clinical our survival in active data generate rates profile to to non-small XX% cell greater brain and overall
have to in identification field and GXXC opportunities development testing of increase our are are to assist market patients. to eligible both we team organizations biotech, been to experience launching giving in working with extensive provider response, KRAS and products. success healthcare teams demonstrated improve cancer and both pharma able access lung In outcomes. oncology a across patient Second, attract and talent top There top us activities
Third a have we singular on adagrasib. commercialization our with focus purpose-built team
and execution speed We optimized as success digitization this program. Fourth, for In in positive of terms launch initial make well both an with of out the built on and integration, the have very to functions. we're opportunity we about and optimization living investing the the of a with deliver invest this executing across on in patients focus have launch team long-term summary, as of on value design the to capital necessary cancer. and excited impact grass potential differentiated
availability in at we leadership in to who the submission From for team we to completed Union. us non-small and CFO to development prior addition U.S. submission acquired commercial of adagrasib the as launch will have prepare Medicines the from one the an finance expertise bringing application adagrasib stage in perspective, to the European beneficial the industry, strategy our important marketing bringing European patients of of the navigating a has closer finalize adagrasib's step joined US. invaluable Beyond strategic with research cell and the biopharmaceutical experience the US, patients possibly considerable with important received our therapy in wealth second including a management This GXXC of career harboring in authorization Mirati, her treatment lung her quarter. an skill insight. of Laurie to set commercial XX-year an Laurie cancer expanding least a a the which team and Stelzer Agency. we the a of is needs our of the for as systemic company KRAS the stage made mutation and outside transitioning be over
later prudently year. oncology call success enables our launch With the our prepare us for strategy fortunate to I'll turn pipeline to be for position a that across to with we finally and for to flexibility bring very invest Laurie at adagrasib history. FDA Chuck to in a are us the this update. our execute approval successful And provides pending front over strong continue financial in target which pivotal clinical this We on a and
